SYRE Spyre Therapeutics, Inc.

CIK 0001636282 50 ready 8-Ks latest June 15, 2026, 8:01 AM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing June 15, 2026, 8:01 AM ET

Top materiality 0.95

Event mix other_material ×30 · earnings ×9 · leadership ×4

Sentiment 18 pos · 6 neg · 26 neu

Latest earnings reported 2026-Q1

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for SYRE

Highest-materiality recent filing

Aeglea appoints Cameron Turtle as PEO; discloses substantial doubt about going concern

October 10, 2023, 7:59 PM ET other material materiality 0.95 negative item 5.02 item 8.01 item 9.01 ◈ executive_change

Cameron Turtle appointed principal executive officer effective Oct 6, 2023; previously COO since June 2023.
Company received SEC waiver to file abbreviated financials for Spyre acquisition; net liabilities assumed of $17.0M.

Read filing →

June 15, 2026, 8:01 AM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Spyre reports positive Phase 2 topline data for SPY002 in ulcerative colitis; met primary endpoint

SPY002 achieved primary endpoint: 10.7-point RHI reduction (p<0.0001) at 12 weeks.
June 1, 2026, 4:01 PM ET other material materiality 0.55 neutral item 8.01 item 9.01

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

License field expanded from inflammatory bowel disease to all human disease indications.
May 29, 2026, 4:45 PM ET other material materiality 0.30 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4◈ executive_change

Spyre Therapeutics stockholders approve amended ESPP; director Peter Harwin resigns

Stockholders approved amended and restated 2016 ESPP (66.9M for, 45.5K against) at May 27 annual meeting.
May 5, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Spyre Q1 net loss $69M; SPY001 hits primary endpoint; cash runway to H2 2029

Net loss of $69.0M in Q1 2026 vs $44.8M in Q1 2025; R&D expenses $60.4M (up from $41.6M).
April 16, 2026, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 9.01 ◈ Material Agreements

Spyre Therapeutics raises ~$463.5M in underwritten public offering of 7.475M shares at $62.00/share

Gross proceeds of ~$463.5M from 7.475M shares including full exercise of over-allotment option at $62.00/share.
April 13, 2026, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Spyre SPY001 meets primary endpoint in Phase 2 SKYLINE Part A for UC; 40% clinical remission

SPY001 achieved primary endpoint with RHI reduction of 9.2 points (p<0.0001) at Week 12.
April 13, 2026, 7:59 PM ET other material materiality 0.70 positive item 2.02 item 8.01

Spyre reports preliminary $741M cash; suspends ATM offering

Preliminary cash, equivalents and marketable securities of $741M as of March 31, 2026.
February 19, 2026, 6:59 PM ET earnings materiality 0.55 neutral item 2.02 item 9.01

Spyre Therapeutics reports Q4 2025 net loss of $62.5M; cash $756.5M; Phase 2 readouts expected Q2/Q4 2026

Q4 2025 net loss $62.5M (vs $56.3M Q4 2024); R&D expense $44.6M (vs $50.5M).
January 12, 2026, 6:59 PM ET leadership materiality 0.70 positive item 7.01 item 9.01

Spyre appoints CCO, accelerates SPY001 readout to Q2; six proof-of-concept reads expected in 2026

Appointed Kate Tansey Chevlen as CCO; previously Amgen VP, Global Marketing Head for Immunology.
November 4, 2025, 6:59 PM ET other material materiality 0.85 positive item 2.02 item 7.01 item 8.01 item 9.01

Spyre Therapeutics reports positive Phase 1 data for SPY003 with ~85-day half-life; Q3 net loss $11.2M

SPY003 Phase 1 interim results show half-life of ~85 days, supporting potential quarterly or twice annual maintenance dosing.
October 15, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 9.01

Spyre Therapeutics raises ~$316M in public offering of 17M shares at $18.50

Sold 14,864,865 shares at $18.50; underwriters exercised option for 2,229,729 additional shares.
October 14, 2025, 7:59 PM ET other material materiality 0.50 neutral item 2.02

Spyre Therapeutics expects $486.2M cash as of Sept 30, 2025

Preliminary unaudited cash, cash equivalents and marketable securities of ~$486.2M as of Sept 30, 2025.
August 5, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Spyre Q2 net loss $36.7M; cash $526.6M; initiates Phase 2 SKYLINE-UC; TL1A data positive

Net loss of $36.7M for Q2 2025 ($38.8M in Q2 2024); stock-based compensation $9.4M.
June 17, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Spyre reports positive Phase 1 data for SPY002 & SPY072; half-life ~75 days, Phase 2 trials initiated

SPY002 and SPY072 well tolerated up to 1500 mg; no serious AEs, no TEAEs >Grade 2, no discontinuations.
June 2, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Spyre Therapeutics stockholders elect three Class III directors at 2025 annual meeting

Elected Peter Harwin (38.2M for, 8.0M withheld), Michael Henderson (45.4M for, 0.7M withheld), Sandra Milligan (37.6M for, 8.6M withheld) as Class III directors.
May 8, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Spyre Therapeutics Q1 net loss $44.8M; cash $564.8M; on track for Phase 2 starts mid-2025

Cash, cash equivalents, and marketable securities of $564.8M as of March 31, 2025.
March 6, 2025, 6:59 PM ET other material materiality 0.75 negative item 4.01 item 9.01 ◈ Auditor Changes ×2

Spyre dismisses PwC as auditor, appoints KPMG; discloses material weakness in controls

PwC dismissed as auditor effective Feb 28, 2025; KPMG appointed as new independent auditor for FY2025.
February 27, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Spyre reports Q4 2024 net loss of $56.3M; cash $603M; pipeline on track with Phase 2 trials in 2025

Cash, cash equivalents, and marketable securities $603.1M as of Dec 31, 2024; cash runway into H2 2028.
January 13, 2025, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 8.01 item 9.01

Spyre Therapeutics expands SPY002 into RA; $603M cash runway into H2 2028

Preliminary cash, cash equivalents, and marketable securities of ~$603M as of Dec 31, 2024, funding operations into H2 2028.
November 19, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 9.01

Spyre Therapeutics prices $200M public offering of 7.275M shares at $27.50

Offering includes 7,275,000 shares of common stock at $27.50; underwriters have 30-day option for 1,091,250 additional shares.
November 18, 2024, 6:59 PM ET other material materiality 0.85 negative item 4.02 item 8.01 ◈ Auditor Changes

Spyre Therapeutics restates net loss per share from 2023-2024; material weakness in controls

Restating audited and unaudited financials from Dec 31, 2023 to Sep 30, 2024 due to misapplication of GAAP in EPS calculation for preferred stock.
November 12, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Spyre reports positive Phase 1 data for SPY001; half-life >90 days, supports Q3M-Q6M dosing

SPY001 half-life >90 days (300mg SC) and >100 days (600mg SC), ~4-fold greater than vedolizumab's 25-day half-life.
November 7, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Spyre Therapeutics reports Q3 net loss of $69M; pipeline on track with SPY001 Phase 1 data by year-end

Net loss of $69.0M in Q3 2024 (vs $40.1M in Q3 2023); R&D expenses rose to $44.7M from $24.7M.
October 15, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 7.01 item 8.01 item 9.01

Spyre accelerates SPY003 (IL-23) to first-in-human Q1 2025; licenses from Paragon for up to $22M

First-in-human dosing of SPY003 (anti-IL-23) now expected Q1 2025; interim data expected H2 2025.
August 8, 2024, 7:59 PM ET other material materiality 0.00 neutral

Spyre Therapeutics files 8-K/A to correct date on cover page of prior filing

Amendment corrects clerical error on cover page date of Original 8-K filed August 7, 2024.
August 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Spyre Q2 net loss narrows to $38.8M; SPY001 Phase 1 dosed, interim data by year-end

Net loss narrowed to $38.8M in Q2 2024 from $217.1M in Q2 2023; cash and securities $426.3M.
May 30, 2024, 7:59 PM ET other materiality 0.30 neutral item 7.01

Spyre Therapeutics updates share count: 50.8M actual, 65.3M pro forma

As of May 29, 2024, common shares outstanding: 50,782,384.
May 15, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 5.02 item 5.03 item 5.07 item 7.01 item 9.01 ◈ Shareholder Votes ×7◈ Material Agreements ×2◈ executive_change◈ Governance Changes

Spyre licenses Paragon’s α4ß7 and TL1A antibodies, appoints Dr. Milligan to board, and approves Series B conversion

Entered exclusive license with Paragon for α4ß7 and TL1A antibodies; up to $22M milestones per program plus low single-digit royalties.
May 9, 2024, 7:59 PM ET other material materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Spyre reports Q1 net loss $43.9M; cash $485M; SPY001 on track for FIH Q2 2024

Net loss of $43.9M for Q1 2024, including $13.8M non-cash stock comp; vs $18.4M loss in Q1 2023.
April 25, 2024, 7:59 PM ET other material materiality 0.30 neutral item 3.02 item 9.01

Spyre exchanges 90,992 Series A Preferred shares for 3.64M common shares

90,992 shares of Series A Non-Voting Convertible Preferred Stock exchanged for 3,639,680 shares of common stock.
March 18, 2024, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 5.03 item 3.02 item 7.01 item 9.01 ◈ Governance Changes◈ Material Agreements

Spyre Therapeutics announces $180M private placement of convertible preferred stock

Spyre raises ~$180M via PIPE: 121,625 Series B convertible preferred shares at $1,480 each.
February 29, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Spyre Q4 2023 net loss $63.2M; cash $339.6M; pipeline on track with SPY001 FIH H1 2024

Net loss $63.2M in Q4 2023 vs $18.8M in Q4 2022; cash $339.6M as of Dec 31, 2023.
February 5, 2024, 6:59 PM ET leadership materiality 0.55 neutral item 1.01 item 5.02 item 5.03 item 5.05 item 9.01 ◈ executive_change ×2◈ Governance Changes ×2

Spyre appoints Mark McKenna as director; CEO severance amended

Alison Lawton resigned from Board effective Feb 1, 2024; no disagreement cited.
January 18, 2024, 6:59 PM ET other materiality 0.35 positive item 3.01

Spyre Therapeutics transfers listing to Nasdaq Global Select Market effective Jan 19, 2024

Received approval from Nasdaq to transfer listing from Capital Market to Global Select Market.
December 8, 2023, 6:59 PM ET debt materiality 0.85 neutral item 1.01 item 5.03 item 3.02 item 7.01 item 9.01 ◈ Governance Changes◈ Material Agreements

Spyre raises $180M PIPE via 6M common shares at $15 and 150K Series B convertible preferred

6,000,000 common shares at $15/share and 150,000 Series B preferred shares at $600/share (convertible into 40 common each).
November 28, 2023, 6:59 PM ET leadership materiality 0.75 positive item 5.02 item 5.03 item 7.01 item 9.01 ◈ executive_change ×3◈ Governance Changes

Spyre Therapeutics appoints Cameron Turtle CEO; name change to Spyre, ticker SYRE effective Nov 28

Cameron Turtle, previously COO, appointed CEO and director; $625K base, 55% target bonus, option for 374K shares at $10.39.
November 24, 2023, 6:59 PM ET other material materiality 0.65 neutral item 5.03 item 5.07 item 7.01 item 9.01 ◈ Shareholder Votes ×4◈ Governance Changes

Aeglea shareholders approve increase in authorized shares to 400M and preferred conversion

Authorized common shares increased from 20M to 400M via Certificate of Amendment.
November 15, 2023, 6:59 PM ET other material materiality 0.65 negative item 8.01 item 9.01

Aeglea recasts FY2022 financials for 1-for-25 reverse split; going concern warning persists

1-for-25 reverse stock split effective Sept 8, 2023; authorized shares cut from 500M to 20M.
November 9, 2023, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Aeglea BioTherapeutics Q3 2023 net loss $40.1M; cash $204.9M; IBD pipeline on track

Net loss $40.1M in Q3 2023 vs $18.2M a year ago, reflecting $24.7M R&D (+106% YoY) and $21.8M other expense.
October 24, 2023, 7:59 PM ET other materiality 0.30 neutral item 7.01 item 9.01

Aeglea BioTherapeutics posts corporate presentation showing anti-TL1A antibody SPY002 with picomolar potency

Non-clinical data for SPY002 (anti-TL1A antibody) show monomer and trimer binding at picomolar potencies.
October 10, 2023, 7:59 PM ET other material materiality 0.95 negative item 5.02 item 8.01 item 9.01 ◈ executive_change

Aeglea appoints Cameron Turtle as PEO; discloses substantial doubt about going concern

Cameron Turtle appointed principal executive officer effective Oct 6, 2023; previously COO since June 2023.
October 5, 2023, 7:59 PM ET other material materiality 0.30 neutral item 1.01

Aeglea amends Paragon agreement, commits to annual 1% option grants for 2023-2024

Annual option grant of 1% of outstanding Aeglea common stock (fully-diluted) to Parapyre for calendar years 2023 and 2024.
September 25, 2023, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.01 item 5.02 item 9.01 ◈ executive_change ×2◈ Listing & Compliance Notices◈ Material Agreements

Aeglea regains Nasdaq compliance, enters WuXi Biologics deals, details CFO separation

Regained Nasdaq minimum bid price compliance after 1-for-25 reverse stock split effective Sept 8, 2023.
September 8, 2023, 7:59 PM ET other material materiality 0.50 neutral item 3.03 item 5.03 item 7.01 item 8.01 item 9.01 ◈ Governance Changes

Aeglea Biotherapeutics effects 1-for-25 reverse stock split and reduces authorized shares to 20M

Reverse stock split at 1-for-25 ratio effective Sept 8, 2023; no fractional shares issued; cash in lieu.
September 5, 2023, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change

Aeglea appoints Scott Burrows as CFO, Heidy Abreu King-Jones as CLO; prior CFO transitions to advisory role

Scott Burrows appointed CFO effective Sept 1, 2023, succeeding Jonathan Alspaugh; base salary $455K, target bonus 40%, sign-on $115K.
August 11, 2023, 7:59 PM ET other material materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Aeglea closes Spyre asset acquisition, raises $210M, sells pegzilarginase, reports Q2 loss

Acquired Spyre's IBD pipeline (α4β7 and TL1A) for stock; raised $210M gross via Series A preferred private placement.
August 11, 2023, 7:59 PM ET other material materiality 0.60 negative item 1.02 ◈ Material Agreements

Aeglea BioTherapeutics terminates Austin office lease, pays $2M termination fee

Terminated lease for Suites 100, 110, and 150 at 805 Las Cimas Parkway, Austin, TX effective Aug 8, 2023.
July 27, 2023, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 1.02 item 2.01 item 7.01 item 8.01 item 9.01 ◈ Material Agreements ×2◈ M&A Transactions

Aeglea sells global rights to pegzilarginase to Immedica for $15M upfront + up to $100M milestones

Sold pegzilarginase (for Arginase 1 Deficiency) to Immedica for $15M upfront and up to $100M in milestone payments.
July 14, 2023, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

Aeglea BioTherapeutics transfers listing to Nasdaq Capital Market to address bid price deficiency

Received notice of Minimum Bid Price non-compliance on Jan 13, 2023; initial grace period ended July 12, 2023.
June 23, 2023, 7:59 PM ET M&A materiality 0.85 neutral item 1.01 item 5.03 item 2.01 item 3.02 item 5.02 item 7.01 item 9.01 ◈ executive_change ×7◈ Material Agreements ×2◈ Governance Changes◈ M&A Transactions

Aeglea BioTherapeutics completes acquisition of Spyre Therapeutics, raises $210M in PIPE financing

Aeglea issued 13,013,636 common shares and 364,889 Series A Preferred shares to Spyre stockholders.